Physician profile
Douglas Michael Smith
NPI 1518285725
$46,071.35
in general payments reported to CMS, 2019-2025
9 companies · $3,533 in 2025
The $3,533 reported for 2025 was more than what 84% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,100 · 2021: $2,062 · 2022: $15K · 2023: $11K · 2024: $12K · 2025: $3,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $3,665 · Travel and Lodging: $2,082 · Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,585.00 |
| Consulting Fee | $3,665.00 |
| Travel and Lodging | $2,081.60 |
| Food and Beverage | $286.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $35,608.13 | 2022-2025 | Fintepla |
| Zogenix INC. | $4,112.50 | 2020-2021 | |
| Ucb Biosciences INC. | $2,500.00 | 2025 | Fintepla |
| Upsher-Smith Laboratories LLC | $1,389.04 | 2024 | |
| Pyros Pharmaceuticals, INC. | $1,300.00 | 2023 | |
| Jazz Pharmaceuticals INC. | $1,065.32 | 2023-2024 | |
| Sk Life Science, INC. | $49.82 | 2021 | |
| Nobelpharma America, LLC | $33.34 | 2025 | |
| Neuropace, INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.